Stockreport

Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF about $2.2 billion in cash, paying $15.50 per share, a 39% premium to the prior close, as it looks to broaden its vaccines portfolio beyond its flu franchise. The announ [Read more]